According to a new report Europe Fusion Biopsy Market, published by KBV research, the Europe Fusion Biopsy Market would witness market growth of 11.1% CAGR during the forecast period (2020-2026).
The Germany market dominated the Europe Fusion Biopsy Market by Country in 2019, growing at a CAGR of 10.3 % during the forecast period. The UK market is exhibiting a CAGR of 10% during (2020 - 2026). Additionally, The France market is anticipated to grow at a CAGR of 12.4% during (2020 - 2026).
The Hospitals market dominated the Russia Fusion Biopsy Market by End Uses in 2019, thereby, achieving a market value of $27.2 million by 2026. The Ambulatory care centers market is expected to witness a CAGR of 13.3% during (2020 - 2026).
The Transrectal market dominated the Spain Fusion Biopsy Market by Route in 2019, and would continue to be a dominant market till 2026. The Transperineal market is experiencing highest CAGR of 17.9% during (2020 - 2026).
Structural Insights: https://www.kbvresearch.com/europe-fusion-biopsy-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Koninklijke Philips N.V., Hitachi, Ltd., Baxter International, Inc. (MedCom), Esaote SpA, Eigen, KOELIS, Inc., Focal Healthcare, Inc. and UC-Care Medical Systems Ltd.
By End Use
By Route
By Country
Companies Profiled
Unique Offerings from KBV Research
Unique Offerings 
